| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | Ziihera (zanidatamab-hrii) first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) BreakthroughPriorityAccelerated | PDUFA | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | |
PDUFA Date example | Ziihera (zanidatamab-hrii) first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) BreakthroughPriorityAccelerated | PDUFA | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | |
PDUFA Date example | Ziihera (zanidatamab-hrii) first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) BreakthroughPriorityAccelerated | PDUFA | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Zymeworks Inc.$25.88
-0.7 (-2.59%)
C 44Pipeline Score Fair Value Pharma · Commercial
Market Cap
1.88 B
EPS
-1.37
P/E Ratio
-
Value Trade
19.47 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.41 M
R&D Expenses
34.46 M
Operating CF
-45.72 M
Total Assets
478.21 M
Total Liabilities
314.63 M
Equity
163.59 M
D/E Ratio
12,345
4.53 %
Week
-9.82 %
1 Month
10.58 %
3 Month
7.51 %
6 Month
-14.43 %
5 Year
89.7 %
All Time
Cash Data
Cash Position
403.84 M
Monthly Burn
15.24 M
Runway
24.6 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
483.25 K
52 Week Range
11.02 - 29.75
% held by Insiders
4.3 %
% held by Institutions
98.94 %
Enterprise Value
1.78 B
Total Shares
73.77 M
Short %
9.5 %
Float Shares
45.96 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zymeworks Inc.
264Total events
15Upcoming
73Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 15
Dec 2026
T2Runway Guidance Update
Cash resources expected to fund operations through at least end of 2026
2027
T2Pipeline Prioritization
Progress product candidates from ADVANCE R&D programs into clinical studies by 2027 and beyond
Q1 2027
T2Milestone Payment
Expected $100 million milestone payment from Royalty Pharma related to TRELEGY ELLIPTA global net sales
TBD
T1Full Results
Data from Part 2a to be presented at a future medical meeting to inform dose selection
TBD
T2Milestone Payment
Anticipated $440M in regulatory milestone payments for Ziihera approvals in US, EU, Japan, China
TBD
T2Milestone Payment
Potential near-term milestone payments for Ziihera regulatory approvals in GEA totaling $440M
Event history 249
Jun 18, 2026
▲Partnership / LicenseCorporate
Partnership with Gandeeva to use cryo-EM for antibody drug discovery
Jun 14, 2026
▲Oral PresentationZW191Presentation
Presented new Phase 1 data for ZW191 at ESMO Gynaecological Cancers Congress 2026
platinum-resistant ovarian cancer, endometrial cancersource ↗
Jun 14, 2026
▲Enrollment CompleteZW191Trial
Completed enrollment in Part 2a dose optimization cohort (~60 PROC patients randomized to 6.4 or 9.6 mg/kg Q3W)
platinum-resistant ovarian cancersource ↗
Jun 2026
◆Oral PresentationZanidatamabApprovedPresentation
Jazz to present PD-L1 subgroup data from HERIZON-GEA-01 at ASCO
first-line HER2-positive GEAsource ↗
Jun 2026
◆Interim AnalysisZanidatamabApprovedTrial
Second interim overall survival analysis for HERIZON-GEA-01 expected mid-2026
first-line HER2-positive GEAsource ↗
May 14, 2026
May 7, 2026
▲Runway Guidance UpdateCorporate
Expect cash resources to fund operations beyond 2028, including anticipated milestone payments
Drug Pipeline Intelligence
C44
Pipeline Score $497M
Pipeline ValueFair Value
Valuation Signal6
Drugs Scored0.9x
rNPV / MCap Top 63%
Micro Cap (rank 338 of 911)
Percentile RankZymeworks Inc. carries a moderate pipeline score (44/100), with $1.2B risk-adjusted pipeline value, led by Futibatinib in Biliary Tract Neoplasms (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Futibatinib Small molecule | Biliary Tract Neoplasms | Phase 3 | NCT05615818 | 42% | $871M | RECRUITING | 800 | - | - | Jun 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ZW191 Fast Track | platinum-resistant ovarian cancer and endometrial cancer | Phase 1 | 2026-06-14 | c ORR FRα positive: 78.6%; c ORR FRα negative: 47.4%; overall c ORR: 58.8%; c ORR dose range: 65.2%; c ORR endometrial FRα negative: 40.0%; disease control rate FRα positive: 100.0%; disease control rate FRα negative: 89.5%; median progression free survival: 7.6 months Read More | Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Read More | |
ZW191 Fast Track | platinum-resistant ovarian cancer and endometrial cancer | Phase 1 | 2026-06-14 | c ORR FRα positive: 78.6%; c ORR FRα negative: 47.4%; overall c ORR: 58.8%; c ORR dose range: 65.2%; c ORR endometrial FRα negative: 40.0%; disease control rate FRα positive: 100.0%; disease control rate FRα negative: 89.5%; median progression free survival: 7.6 months Read More | Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Read More | |
ZW191 Fast Track | platinum-resistant ovarian cancer and endometrial cancer | Phase 1 | 2026-06-14 | c ORR FRα positive: 78.6%; c ORR FRα negative: 47.4%; overall c ORR: 58.8%; c ORR dose range: 65.2%; c ORR endometrial FRα negative: 40.0%; disease control rate FRα positive: 100.0%; disease control rate FRα negative: 89.5%; median progression free survival: 7.6 months Read More | Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZYME
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ZYME Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZYMEZymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks has announced its acquisition of Theravance Biopharma for $17 per share, totaling approximately $929 million. This acquisition includes YUPELRI®, the only approved nebulized LAMA for COPD, which is expected to enhance Zymeworks' portfolio and generate significant cash flow. The deal is supported by a non-recourse financing structure, minimizing capital risk and is anticipated to close in the second half of 2026.
Read more →ZYMEGandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
Gandeeva Therapeutics and Zymeworks have formed a partnership to utilize cryo-electron microscopy (cryo-EM) for antibody drug discovery. This collaboration aims to visualize antibody-antigen interfaces at high resolution, particularly focusing on small and flexible antigens. The ability to obtain near-atomic resolution structures is expected to significantly enhance the selection and optimization of antibody leads.
Read more →ZYMEZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks presented promising Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, at the ESMO Gynaecological Cancers Congress 2026. The data revealed a confirmed objective response rate of 78.6% in FRα-positive ovarian cancer patients and 47.4% in FRα-negative patients. The therapy exhibited a favorable safety profile, with manageable adverse events, supporting its continued clinical development.
Read more →ZYMEBeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
Read more →ZYMEPhase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Read more →ZYMEZymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock Vancouver, British Columbia (
Zymeworks Inc. has announced a share repurchase program allowing for the repurchase of up to $125 million of its common stock. This decision is part of a strategic initiative to enhance capital allocation and provide returns to shareholders, while also preserving financial flexibility to invest in research and development projects. The company has terminated its previous repurchase program from 2025, having bought back over 4 million shares. The new program demonstrates Zymeworks' focus on long-term value creation.
Read more →ZYMEZymeworks Announces Participation in Upcoming Investor Conferences - May 13, 2026
Zymeworks Inc. announced its participation in upcoming investor conferences, highlighting its commitment to engaging with the investment community. The company is focused on managing a portfolio of licensed healthcare assets and developing innovative biotherapeutics targeting difficult-to-treat diseases. Zymeworks continues to advance its pipeline, leveraging proprietary technology and strategic partnerships.
Read more →ZYME▼ -10.2%on this newsshared move
Zymeworks to Present at Respiratory Innovation Summit
Zymeworks to Present at Respiratory Innovation Summit
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab i
Zymeworks Inc. reported its financial results for Q1 2026, highlighting significant regulatory achievements for zanidatamab, which has a PDUFA date set for August 25, 2026. The company also shared promising clinical data for ZW191, showing a 56% objective response rate in ovarian cancer patients. Zymeworks is financially robust, with $403.8 million in cash and equivalents. Additionally, changes to the leadership team were announced to improve strategic execution.
Read more →ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Read more →ZYMEU.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
Read more →ZYMEJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Read more →ZYMEZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
Zymeworks presented promising Phase 1 data for ZW191, an ADC targeting folate receptor alpha, at the AACR Annual Meeting 2026. The therapy showed a 61% confirmed objective response rate in platinum-resistant ovarian cancer and demonstrated manageable safety. The study supports further development of ZW191 for patients with limited treatment options in ovarian and endometrial cancers.
Read more →ZYMEZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Read more →ZYMEZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Zymeworks Inc. will report its first quarter 2026 financial results on May 7, 2026, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the results and provide a corporate update. The event will be accessible via Zymeworks' website.
Read more →ZYMEZymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Read more →ZYMEZymeworks to Present at the AACR Oncology Industry Partnering Event
Zymeworks to Present at the AACR Oncology Industry Partnering Event
Read more →ZYMEZymeworks Appoints Kristin Stafford as Chief Financial Officer
Zymeworks Inc. has appointed Kristin Stafford as Chief Financial Officer, effective April 1, 2026. Stafford brings significant experience from her previous roles, including at Royalty Pharma and Ernst & Young. Her expertise is expected to contribute to Zymeworks' strategic goals and operational excellence as the company advances its biotherapeutics pipeline.
Read more →ZYMEZymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Zymeworks has been granted Fast Track designation by the FDA for ZW191, an antibody-drug conjugate targeting folate receptor-α, aimed at treating advanced or metastatic platinum-resistant ovarian cancer. The ongoing Phase 1 clinical trial is assessing the drug's safety and preliminary anti-tumor activity. This designation underscores Zymeworks' commitment to addressing significant unmet medical needs in oncology.
Read more →ZYMEZymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. has announced its participation in two upcoming investor conferences. The management will engage in virtual meetings and present at the Needham 25th Annual Virtual Healthcare Conference on April 15, followed by the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21. This participation highlights Zymeworks' commitment to investor engagement and its ongoing development of innovative biotherapeutics.
Read more →ZYMEZymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Read more →ZYMEZymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Zymeworks announced the presentation of new clinical and preclinical data at the AACR Annual Meeting, showcasing their ADC programs, including ZW191, which targets folate receptor alpha. The data highlights ZW191's potential effectiveness in advanced solid tumors and the promising activity of new ADC candidates against RAS-mutated cancers. The presentations will occur between April 17-22, 2026, in San Diego, CA.
Read more →ZYMEZymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Zymeworks has entered into a $250 million royalty-backed note financing agreement with Royalty Pharma. The deal allows Zymeworks to receive 30% of worldwide tiered royalties on Ziihera sales, while retaining 70% of the royalties during the repayment period. This funding is aimed at strengthening Zymeworks' balance sheet and supporting its strategic initiatives, including stock repurchases and potential acquisitions.
Read more →ZYMEZymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Zymeworks Inc. provided a corporate update alongside its financial results for 2025, reporting a 39% increase in total revenue to $106 million. The company highlighted significant milestones for its HER2-targeted therapy, Ziihera, and announced a $250 million royalty-backed financing arrangement with Royalty Pharma. Despite a net loss of $81.1 million, Zymeworks maintains a strong cash position and is focused on executing its strategic priorities in 2026.
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Supplemental Biologics License Application for Ziihera (zanidatamab-hrii) to be completed by our partner Jazz i
Zymeworks has released its fourth quarter and full year 2025 financial results, reporting a revenue increase of 39% and a 34% reduction in net loss compared to 2024. The company is preparing to submit a Supplemental Biologics License Application for its drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, with a projected launch between late 2026 and early 2027. Additionally, Zymeworks highlighted its innovative financing strategy through a $250 million royalty-backed note, which is intended to support its ongoing share repurchase program and future acquisitions.
Read more →ZYMEZymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Zymeworks Inc. will report its fourth quarter and full year 2025 financial results on March 2, 2026. A conference call and webcast will follow the announcement at 8:30 am ET to discuss the results and provide a corporate update. The company is known for its innovative biotherapeutics aimed at challenging diseases.
Read more →ZYMEZymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Read more →ZYMEZymeworks Outlines Strategic Priorities and Outlook for 2026
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Read more →ZYME▼ -5.1%on this news
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Read more →ZYMEZymeworks Outlines Strategic Priorities and Outlook for 2026 Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at A
Zymeworks has outlined its strategic priorities for 2026 following a transformative year in 2025. The company reported substantial advancements in its clinical programs, especially for its pipeline assets, Ziihera and pasritamig. With a strong financial foundation, Zymeworks plans to leverage revenues from partnered programs while pursuing strategic acquisitions. Moreover, the firm has authorized a $125 million share repurchase program to bolster shareholder value amidst a broader focus on sustainable growth and disciplined capital allocation.
Read more →ZYMEZymeworks Announces Participation in Upcoming Conferences
Zymeworks Announces Participation in Upcoming Conferences
Read more →ZYMEZymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets Strategy will combine internal innovation, licensing, and strategic acquisi
Zymeworks Inc. has unveiled a strategic initiative to enhance revenue from its licensed products, focusing on building a diversified portfolio. This strategy hinges on leveraging expected cash flows from upcoming regulatory approvals for Ziihera and pasritamig. The company anticipates significant milestone payments and royalty revenues, positioning itself as a royalty-driven organization. Zymeworks aims to reinvest proceeds from product commercialization while maintaining a focus on internal R&D and strategic partnerships.
Read more →ZYMEZymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Read more →ZYME▲ +29%on this newsshared move
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastr
Zymeworks announced positive topline results from the Phase 3 HERIZON-GEA-01 trial, demonstrating that Ziihera (zanidatamab-hrii), in combination with chemotherapy and possibly the PD-1 inhibitor Tevimbra, is effective for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The drug's safety profile aligns with previous results, indicating no new risks. Expectations are set for Jazz Pharmaceuticals to present the findings at a medical meeting and seek adoption into NCCN Guidelines. Zymeworks looks to expand Ziihera's regulatory approval as a leading therapy for this indication.
Read more →ZYMEZymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Read more →ZYMEZymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference
Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor- (FR ), presented at the AACR-NC
Zymeworks Inc. reported its financial results for Q3 2025 and provided an update on its clinical programs. The company showcased promising Phase 1 data for its antibody-drug conjugate ZW191, achieving a 53% overall objective response rate. Additionally, the first patient has been dosed in the Phase 1 trial of ZW251 for hepatocellular carcinoma. Zymeworks also achieved a significant milestone payment of $25 million from Johnson & Johnson, while highlighting a cash runway projected into the second half of 2027.
Read more →ZYMEZymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Read more →ZYMEZymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
Read more →ZYMEZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Read more →ZYMEZymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
Read more →ZYMEZymeworks Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer Annual Meeting
Zymeworks Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer Annual Meeting
Read more →ZYMEZymeworks Presents Preclinical Data on ZW1528 at the European Respiratory Society Annual Congress
Zymeworks Presents Preclinical Data on ZW1528 at the European Respiratory Society Annual Congress
Read more →ZYMEZymeworks Announces Presentation at the European Respiratory Society (ERS) Congress 2025
Zymeworks Announces Presentation at the European Respiratory Society (ERS) Congress 2025
Read more →ZYME▼ -5.4%on this news
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager Vancouver, British Columbia (
Zymeworks Inc. has announced the voluntary discontinuation of the clinical development of ZW171, a mesothelin-directed T cell engager. The decision follows the completion of planned dose escalation trials, where it was determined that the therapy's benefit-risk profile was not in line with expectations. While this outcome is disappointing, Zymeworks emphasizes its commitment to advancing other candidates in its pipeline, including ongoing trials for ZW191 and ZW251. The company remains focused on its broader goals despite this setback.
Read more →ZYMEZymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry Vancouver, British Columbia (
Zymeworks Inc. has announced the appointments of Greg Ciongoli and Robert E. Landry to its Board of Directors, effective August 10, 2025. Both appointees bring extensive financial and strategic leadership experience, which the company believes will enhance its growth strategy. Zymeworks is currently advancing its development programs, particularly with zanidatamab, which has received regulatory approvals in key markets. The company is optimistic about upcoming clinical data and its overall growth trajectory.
Read more →ZYMEZymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with fir
Zymeworks Inc. reported its financial results for the second quarter of 2025, detailing significant progress including the FDA's clearance of their IND application for ZW251. The company highlighted international approval for zanidatamab in the treatment of HER2-positive biliary tract cancer and substantial revenue increases from existing partnerships in the quarter. With a strong cash position of $333.4 million, Zymeworks plans to initiate multiple Phase 1 trials in the coming year and aligns its strategy around anticipated milestone streams and royalty revenues. This update reflects the company's ongoing commitment to advancing its oncology and other therapeutic programs.
Read more →ZYMEZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Read more →ZYME▲ +7.1%on this news
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Read more →ZYMEZymeworks Wins Life Sciences BC 2025 Company of the Year Award
Zymeworks Wins Life Sciences BC 2025 Company of the Year Award
Read more →ZYMEZymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer Zanidatamab is the first and only dual HER2-targe
Zymeworks Inc. has announced that the National Medical Products Administration (NMPA) in China has granted conditional approval for zanidatamab, a dual HER2-targeted bispecific antibody, for the treatment of adults with previously treated unresectable or metastatic HER2-positive biliary tract cancer. This marks a significant milestone as it is the first antibody of its kind approved for this indication in China. The approval brings hope to patients with high unmet needs and poor prognoses and could potentially benefit Zymeworks financially through milestone payments and royalties.
Read more →ZYMEZymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
Read more →ZYMEZymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Read more →ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results Six posters presented at the American Association for Cancer Research (AACR) annual meeting Appointment of Dr. Sabeen Mekan as
Zymeworks has provided a corporate update and reported its first quarter 2025 financial results, revealing $321.6 million in cash resources. The company presented six posters during the AACR annual meeting, highlighting advancements in its biotherapeutic pipeline. Additionally, Dr. Sabeen Mekan has been appointed as Senior Vice President of Clinical Development, bringing extensive experience to further enhance the company's oncology portfolio. Zymeworks remains well-capitalized and poised for ongoing developments in cancer treatment and other diseases.
Read more →ZYMEZymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Read more →ZYMEZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
Read more →ZYMEZymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Read more →ZYMEZymeworks to Present Preclinical Data on ZW1528 at the American Thoracic Society Annual Meeting
Zymeworks to Present Preclinical Data on ZW1528 at the American Thoracic Society Annual Meeting
Read more →ZYMEZymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate
Zymeworks Inc. has provided a corporate update alongside its fourth quarter and full year 2024 financial results. The company has initiated first-in-human studies for two key candidates, ZW191 and ZW171, targeting specific cancer indications. Additionally, the FDA granted accelerated approval for Ziihera, expanding Zymeworks' commercial opportunities. Financially, Zymeworks reported $324.2 million in cash resources and aims to utilize these funds into 2027, though it has paused the Phase 1 studies of ZW220 amid resource shifts.
Read more →ZYMEZymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Read more →ZYMEZymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
Read more →ZYMEZymeworks Announces Appointment of Oleg Nodelman to Board of Directors Vancouver, British Columbia (
Zymeworks Inc. has announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Nodelman, the Founder and Managing Director of EcoR1 Capital, brings over two decades of investment management experience in biotechnology. His appointment is part of Zymeworks' ongoing board renewal process aimed at leveraging expertise to enhance growth and support the company's mission of developing innovative therapies. This restructuring aligns with Zymeworks’ commitments toward addressing challenging medical conditions such as cancer and autoimmune diseases.
Read more →ZYMEZymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
Read more →ZYMEZymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Read more →ZYMEZymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 IND applicat
Zymeworks Inc. has outlined its strategic priorities for 2025 and 2026, highlighting a pipeline of investigational new drugs aimed at treating solid tumors. The company has reported significant achievements, including FDA approval for zanidatamab and strong financial resources. They anticipate initiating first-in-human studies for ZW220 and ZW251 in 2025. Zymeworks plans to present at the J.P. Morgan Healthcare Conference in January 2025 to further discuss its innovative approaches and pipeline advancements.
Read more →ZYMEZymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
Read more →ZYME▼ -6%on this news
FDA Grants U.S. Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) Ziihera is the first and only dual
Zymeworks Inc. announced FDA approval for Ziihera (zanidatamab-hrii), a dual HER2-targeted therapy for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. The drug gained accelerated approval following promising clinical trial results demonstrating a 52% objective response rate and a median duration of response of 14.9 months. Zymeworks has partnered with Jazz Pharmaceuticals for its development and commercialization rights, earning an initial milestone payment of $25 million. Continued approval will depend on further confirmation of clinical benefits in ongoing trials.
Read more →ZYME▲ +7.4%on this news
Zymeworks Presents Preclinical Data on ZW171 at the Society for Immunotherapy of Cancer (SITC) Conference
Zymeworks Presents Preclinical Data on ZW171 at the Society for Immunotherapy of Cancer (SITC) Conference
Read more →ZYMEZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Read more →ZYMEZymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical da
Zymeworks Inc. reported its third quarter 2024 financial results, highlighting the dosing of the first patient in a Phase 1 trial evaluating ZW171. The company also presented preclinical data on promising candidates ZW220 and ZW251. With $374.9 million in cash available, Zymeworks anticipates a solid cash runway into the second half of 2027. Additionally, potential breakthroughs are on the horizon with partner Jazz Pharmaceuticals' zanidatamab expected for a potential FDA approval in late November 2024 for patients with biliary tract cancer.
Read more →ZYMEZymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Read more →ZYMEZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Read more →ZYMEZymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Read more →ZYMEDr. Raffaele Colombo Honored as a PharmaVoice 100 Winner
Dr. Raffaele Colombo Honored as a PharmaVoice 100 Winner
Read more →ZYMEZymeworks Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer Annual Meeting
Zymeworks Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer Annual Meeting
Read more →ZYMEZymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Read more →ZYMEZymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Read more →ZYMEZymeworks Showcases New and Updated Clinical Data for Zanidatamab at ESMO 2024
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ESMO 2024
Read more →ZYMEZymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results Reported $395.9 million in cash resources as of
Zymeworks has provided a corporate update alongside its Q2 2024 financial results, reporting significant cash resources of $395.9 million, ensuring operational runway into the second half of 2027. Key developments include the Priority Review designation granted for zanidatamab as a second-line treatment for HER2-positive biliary tract cancer, with a target action date set for November 2024. Additionally, the FDA has cleared IND applications for two investigational products, ZW171 and ZW191, with clinical trials set to commence in the latter half of 2024. Notably, the company has also made the decision to discontinue the development of zanidatamab zovodotin, redirecting resources to more promising candidates.
Read more →ZYMEZymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and
Zymeworks Inc. has announced a Share Repurchase Program amounting to $60 million to buy back its common stock. The company plans to initiate this program with an immediate repurchase of $30 million, reflecting its confidence in future prospects and commitment to delivering value to shareholders. The remaining $30 million is reserved for future repurchases based on market conditions, showcasing strategic flexibility. Overall, this initiative is aimed at enhancing shareholder value while supporting ongoing growth opportunities.
Read more →ZYMEZymeworks Appoints Leone Patterson as Chief Business and Financial Officer Vancouver, British Columbia (
Zymeworks Inc. has announced the appointment of Leone Patterson as its Chief Business and Financial Officer, effective September 1, 2024. Patterson, who has over 20 years of experience in the biotechnology sector, is expected to play a vital role in guiding the company's financial strategies and supporting its growth objectives. This leadership change comes as Zymeworks aims to enhance its pipeline of novel therapies aimed at difficult-to-treat diseases. Zymeworks continues to make progress towards its strategic goals, which include advancing multiple product candidates into clinical studies in the coming years.
Read more →ZYMEZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Read more →ZYME▲ +6.8%on this news
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
Read more →ZYME▼ -5.5%on this news
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Read more →ZYMEZymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Read more →ZYMEIntroducing Pride in Biotech
Introducing Pride in Biotech
Read more →ZYMEZanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Read more →ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results Reported $420.5 million in cash resources as of
Zymeworks Inc. reported its financial results for Q1 2024, revealing $420.5 million in cash resources that could sustain its operations until mid-2027. The company progresses its pipeline, particularly with zanidatamab for biliary tract cancers, as they anticipate a Phase 3 trial initiation later this year. Despite a significant decrease in revenue compared to the previous year, Zymeworks remains committed to advancing innovative solutions in oncology. The company also plans to submit two investigational new drug applications this year, reinforcing its development strategy.
Read more →ZYMEZymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Read more →ZYMEZymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Read more →ZYME▼ -6.6%on this news
Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed
Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed
Read more →ZYMEZymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors Vancouver, British Columbia (
Zymeworks Inc. has announced the appointment of Dr. Neil Gallagher to its Board of Directors, effective April 2, 2024. Dr. Gallagher brings over 20 years of experience in drug development, particularly in oncology, and is expected to enhance the company's governance and oversight. His leadership will aid in advancing Zymeworks' clinical programs and expanding its pipeline of biotherapeutics. This staffing move reflects the company's ongoing commitment to improving the standard of care for patients with challenging diseases.
Read more →ZYMEDocument Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results Reported $456.3 million in cash resources as of
Zymeworks Inc. reported a strong financial position with $456.3 million in cash as of December 31, 2023, allowing projected operational capacity into 2027. The company announced the initiation of a rolling biologics license application (BLA) for its drug zanidatamab in the U.S. for biliary tract cancers, with expected regulatory submission completion set for the first half of 2024. Additionally, two investigational new drug (IND) submissions are planned for the current year, highlighting Zymeworks' commitment to progressing its clinical and preclinical pipeline in innovative therapies. Upcoming data from pivotal trials and presentations at major conferences further indicate a transformative year ahead for the biopharma company.
Read more →ZYMEZymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Read more →ZYMEZymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Read more →ZYMEZymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
Read more →ZYMEZymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors Vancouver, British Columbia (
Zymeworks Inc. has appointed Dr. Alessandra Cesano to its board of directors, effective February 8, 2024, succeeding Dr. Kenneth Hillan. Dr. Cesano's extensive experience in drug development and cancer immunology is expected to enhance the company's governance and pipeline of therapeutics. Her prior roles include serving as Chief Medical Officer at ESSA Pharmaceuticals and NanoString Technologies. Zymeworks aims to leverage her expertise as it focuses on advancing novel oncology treatments for difficult-to-treat cancers.
Read more →ZYMEZymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Read more →ZYMEZymeworks Announces Additional Leadership Appointments
Zymeworks Announces Additional Leadership Appointments
Read more →ZYMEZymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of
Zymeworks Inc. has outlined its strategic priorities for 2024 and 2025, emphasizing its strong financial position with approximately $455 million in cash resources. The company is focused on advancing multiple candidates, including zanidatamab, with significant upcoming clinical trials and potential regulatory approvals in 2025. Leadership changes and a commitment to expand their research pipeline indicate a proactive approach to enhancing their therapeutics portfolio. Zymeworks aims to leverage strategic partnerships to further support their objectives.
Read more →ZYME▲ +8.6%on this news
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital Proceeds expected to extend cash runway into H2 2027 Vancouver, British Columbia (
Zymeworks Inc. has announced a $50 million private placement with EcoR1 Capital to extend its cash runway into the second half of 2027. The proceeds will support the company's 5 by 5 research and development strategy, aiding in the advancement of upcoming investigational new drug application filings for ZW171 and ZW191 in 2024. The private placement, which involves the sale of pre-funded warrants, is expected to close around December 28, 2023, subject to certain closing conditions.
Read more →ZYMEZymeworks Added to Nasdaq Biotechnology Index
Zymeworks Added to Nasdaq Biotechnology Index
Read more →ZYMEUpdated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023
Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023
Read more →ZYMEZymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Announces Participation in Upcoming Investor Conference
Read more →ZYMEZymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results
Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results Net l oss for the first nine months of 20 23 decreased by 44% as compared to the same period in 2022 Cash resources of $390.2
Zymeworks Inc. reported a 44% decrease in net loss for the first nine months of 2023 compared to the same period in 2022, with cash resources of $390.2 million supporting operations through 2026. At the ESMO Annual Congress, positive clinical results for zanidatamab were shared, showing significant antitumor activity and improved quality of life outcomes for patients. Zymeworks has identified ZW251, a new antibody drug conjugate candidate, expecting an IND submission in late 2025, representing a strategic advancement in their product portfolio. Additionally, the company has reacquired rights for zanidatamab zovodotin to advance its clinical development independently.
Read more →ZYMEZymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference
Zymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference
Read more →ZYMEZymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress
Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress
Read more →ZYMEZymeworks To Host Third Quarter 2023 Results Conference Call
Zymeworks To Host Third Quarter 2023 Results Conference Call
Read more →ZYME▲ +8.5%on this newsshared move
Zymeworks Announces New Director Nominee VANCOUVER, British Columbia
Zymeworks Inc. has announced the nomination of Dr. Nancy Davidson to its board of directors during the upcoming annual general meeting on December 7, 2023. This addition is part of the company's strategy to promote diversity in leadership as it aims for five IND filings by the end of 2027. Dr. Davidson is an established expert in oncology, particularly breast cancer, and brings a wealth of clinical experience to the board. Her role is expected to significantly support Zymeworks' goals in developing and commercializing innovative therapies for difficult-to-treat cancers.
Read more →ZYME▲ +8.5%on this newsshared move
Zymeworks Announces New Director Nominee
Zymeworks Announces New Director Nominee
Read more →ZYME▲ +8.5%on this newsshared move
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
Read more →ZYMEZymeworks to Present on Clinical and Preclinical Programs at Multiple Upcoming Medical Conferences
Zymeworks to Present on Clinical and Preclinical Programs at Multiple Upcoming Medical Conferences
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results Net loss for the first six months of 2023 decrease d by 45% as compared to the same period in 2022 Cash resources of $431.4 m
Zymeworks Inc. reported its financial results for the second quarter of 2023, highlighting a significant 45% reduction in net loss compared to the first half of 2022. The company maintains cash resources of $431.4 million, anticipated to fund operations through at least the end of 2026. Recent clinical results for zanidatamab were positively received at the ASCO Annual Meeting, showcasing its potential in treating HER2-amplified cancers. Additionally, Zymeworks announced the nomination of its next IND candidate, ZW220, expected to be filed in the first half of 2025, further advancing its pipeline of therapeutic candidates.
Read more →ZYMEZymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Read more →ZYMEZymeworks To Host Second Quarter 2023 Results Conference Call
Zymeworks To Host Second Quarter 2023 Results Conference Call
Read more →ZYMEZymeworks Appoints New Director Vancouver, British Columbia (
Zymeworks Inc. has appointed Carlos E. Campoy to its board of directors, effective June 30, 2023. Campoy succeeds Dr. Natalie Sacks, who has served successfully for six years. He brings over 25 years of financial and strategic leadership experience in the biotechnology sector to the role. The appointment comes at a crucial time for Zymeworks as it continues to develop novel biotherapeutics, particularly for treating difficult cancers.
Read more →ZYMEZymeworks Appoints New Director
Zymeworks Appoints New Director
Read more →ZYMEZymeworks Set To Join Russell 3000®, Russell 2000®, And Russell Microcap® Indexes
Zymeworks Set To Join Russell 3000®, Russell 2000®, And Russell Microcap® Indexes
Read more →ZYMEJazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Read more →ZYMEZymeworks Announces Participation In Upcoming Investor Conferences
Zymeworks Announces Participation In Upcoming Investor Conferences
Read more →ZYMEZymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023
Read more →ZYMEZymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer Vancouver, British Columbia (
Zymeworks Inc. announced the departure of Neil Klompas, President and Chief Operating Officer, effective June 30, 2023. Klompas has been with the company since 2007 and played a crucial role in its growth and development. His departure has led to expressions of gratitude from the company's leaders, highlighting his contributions to its milestones. He will continue to serve as an advisor during the transition period, ensuring continuity in leadership as Zymeworks focuses on advancing its drug development initiatives.
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, an
Zymeworks Inc. provided its corporate update and financial results for Q1 2023, confirming its operating cash burn guidance of $90-$120 million and cash runway through at least 2026. The company reported a 66% decrease in net quarterly loss, amounting to $24.4 million. It showcased its preclinical antibody-drug conjugate and multispecific antibody therapeutics pipeline at the AACR meeting and announced upcoming presentations at ASCO on its lead product zanidatamab. Zymeworks also strengthened its leadership team by adding Derek J. Miller to its Board of Directors.
Read more →ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
Read more →ZYMEZymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting ZW191 demonstrates strong responses in FR -low expressing patien
Zymeworks Inc. presented new data from its preclinical and clinical development programs during the 2023 American Association for Cancer Research Annual Meeting. Highlights included promising results for ZW191, an antibody-drug conjugate targeting the folate receptor alpha, and ZW171, designed for mesothelin-expressing tumors. These advancements are part of Zymeworks' strategy to expand its therapeutic offerings, with plans to introduce multiple new products into clinical studies by 2027. The developments signal significant progress in their ongoing research into cancer therapies.
Read more →ZYMEZymeworks To Host First Quarter 2023 Results Conference Call
Zymeworks To Host First Quarter 2023 Results Conference Call
Read more →ZYMEZymeworks Announces Appointment of Derek J. Miller to its Board of Directors Vancouver, British Columbia (
Zymeworks Inc. has appointed Derek J. Miller to its board of directors as of April 10, 2023. Miller brings over 20 years of experience in oncology and has previously held significant leadership roles in various biopharma companies. This move is positioned to strengthen Zymeworks' strategic direction, particularly in its collaboration with Jazz Pharmaceuticals and BeiGene on the development of zanidatamab and other antibody-drug conjugates. Miller expresses enthusiasm about contributing to Zymeworks' mission to improve patient outcomes.
Read more →ZYMEZymeworks To Present Updated Data On Multiple Product Candidates At The American Association For Cancer Research (AACR) Annual Meeting
Zymeworks To Present Updated Data On Multiple Product Candidates At The American Association For Cancer Research (AACR) Annual Meeting
Read more →ZYMEDocument Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results 2022 was a year of transformation and change reported $412.5 million in total revenue for the year ended
Zymeworks reported its fourth-quarter and full-year 2022 financial results, highlighting a notable transformation in its business operations. The company achieved total revenue of $412.5 million and reported a net income of $124.3 million, compared to a loss in the previous year. A significant collaboration agreement was formed with Jazz Pharmaceuticals to develop zanidatamab, which has shown promising results in clinical trials. Zymeworks also plans to advance multiple clinical trials and new product candidates through 2024 and beyond.
Read more →ZYMEZymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
Read more →ZYMEZymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
Read more →ZYMEJazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Read more →ZYMEZymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)
Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)
Read more →ZYMEZymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
Read more →ZYMEZymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 Provides updated key priorities and focus on enterprise value framework Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 Vancouver, British Columbia (January 04, 2023) Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced updated k
Read more →ZYME▲ +23.6%on this news
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DU
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, Dec. 21, 2022 Jazz Pharmaceuticals plc (Nasdaq: J
Read more →ZYME▲ +5.1%on this news· ran to +36% by day 3shared move
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab Vancouver, British Columbia (December 19, 2022) Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced positiv
Read more →ZYMEZanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Read more →ZYME▼ -5.2%on this news· ran to -15% by day 1shared move
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS Results show overall confirmed objective response rate (cORR) of 33%, disease control rate (DCR) of 92%, and median p
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS Vancouver, British Columbia (December 9, 2022) Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presen
Read more →ZYMEZymeworks to Transfer Stock Listing to Nasdaq Vancouver, British Columbia (
Zymeworks to Transfer Stock Listing to Nasdaq Vancouver, British Columbia (December 5, 2022) Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that it has elected to transfer its stock exchange li
Read more →ZYMEZymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals Vancouver, British Columbia (
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals Vancouver, British Columbia (November 29, 2022) Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional bio
Read more →ZYMEZymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Read more →ZYME▲ +9%on this news
Zymeworks Presents Preclinical Data on TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference
Zymeworks Presents Preclinical Data on TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference
Read more →ZYMEDocument Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks' lead clin
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks' lead clinical candidate, for total potential payments of up to $1.76 billion
Read more →ZYMENovember is Stomach Cancer Awareness Month
November is Stomach Cancer Awareness Month
Read more →ZYMEZymeworks Early R&D Day Highlights Progress In Development Of Novel Pipeline Assets And Applications Of Proprietary Next-Generation Technology Platforms
Zymeworks Early R&D Day Highlights Progress In Development Of Novel Pipeline Assets And Applications Of Proprietary Next-Generation Technology Platforms
Read more →ZYME▲ +15.9%on this newsshared move
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody Jazz to obtain exclusive development and commercialization rights in k
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receiv
Read more →ZYMEZymeworks to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) Conference
Zymeworks to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) Conference
Read more →ZYMEZymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day
Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day
Read more →ZYME▼ -5.4%on this news
Zymeworks Reports Preliminary Phase 1 Trial Results For Zanidatamab Zovodotin (ZW49) At European Society For Medical Oncology Annual Congress
Zymeworks Reports Preliminary Phase 1 Trial Results For Zanidatamab Zovodotin (ZW49) At European Society For Medical Oncology Annual Congress
Read more →ZYME▼ -28.8%on this news
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
Read more →ZYME▲ +5.6%on this news
Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results
Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results
Read more →ZYME▼ -6.7%on this news
Zymeworks Announces Oral Presentation Of Data From Phase 1 Study Of Zanidatamab Zovodotin (ZW49) In Solid Cancers At European Society For Medical Oncology (ESMO) Congress 2022 In Paris
Zymeworks Announces Oral Presentation Of Data From Phase 1 Study Of Zanidatamab Zovodotin (ZW49) In Solid Cancers At European Society For Medical Oncology (ESMO) Congress 2022 In Paris
Read more →ZYMEZymeworks To Host Second Quarter Results Conference Call
Zymeworks To Host Second Quarter Results Conference Call
Read more →ZYME▼ -9.7%on this news
Zymeworks Statement on U.S. Supreme Court Overturning Roe v. Wade
Zymeworks Statement on U.S. Supreme Court Overturning Roe v. Wade
Read more →ZYMEZymeworks Appoints Dr. Paul Moore As Chief Scientific Officer
Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer
Read more →ZYME▲ +7.8%on this news
Zymeworks Announces Participation In Upcoming Investor Conference
Zymeworks Announces Participation In Upcoming Investor Conference
Read more →ZYME▲ +7.6%on this news· ran to +18% by day 3shared move
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
Read more →ZYME▼ -12.1%on this news
Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI
Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI
Read more →ZYMEZymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Read more →ZYMEZymeworks Announces Presentations At 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting
Zymeworks Announces Presentations At 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting
Read more →ZYMEZymeworks To Host First Quarter 2022 Results Conference Call
Zymeworks To Host First Quarter 2022 Results Conference Call
Read more →ZYMEZymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
Read more →ZYMEZymeworks To Host Fourth Quarter And Full Year 2021 Results Conference Call
Zymeworks To Host Fourth Quarter And Full Year 2021 Results Conference Call
Read more →ZYMEZymeworks Provides Corporate Update On Key Strategic Priorities And Outlook For 2022
Zymeworks Provides Corporate Update On Key Strategic Priorities And Outlook For 2022
Read more →ZYME▼ -6.8%on this news
Zymeworks To Present At 40th Annual J.P. Morgan Healthcare Conference
Zymeworks To Present At 40th Annual J.P. Morgan Healthcare Conference
Read more →ZYME▼ -6.8%on this newsshared move
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
Read more →ZYME▼ -14.9%on this news
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
Read more →ZYME▼ -14.9%on this news
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
Read more →ZYMEZymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric ™ and EFECT ™ Therapeutic Platforms
Read more →ZYMEZymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
Read more →ZYMEZymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA)
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA)
Read more →ZYMEZymeworks to Present at Upcoming Investor Conferences
Zymeworks to Present at Upcoming Investor Conferences
Read more →ZYMEDocument Zymeworks Reports 2021 Third Quarter Financial Results
q3_2021xpressxre.htm EX-99.1 Document Zymeworks Reports 2021 Third Quarter Financial Results
Read more →ZYMEZymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
Read more →ZYMEZymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
Read more →ZYME▲ +9.3%on this news
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Read more →ZYMEZymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Read more →ZYMEDocument Zymeworks Reports 2021 Second Quarter Financial Results
q2_2021xpressxre.htm EX-99.1 Document Zymeworks Reports 2021 Second Quarter Financial Results
Read more →ZYMEZymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric ™ and EFECT ™ Therapeutic Platforms
Read more →ZYMEZymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy
Read more →ZYMEZymeworks to Present at Ladenburg Thalmann Healthcare Conference
Zymeworks to Present at Ladenburg Thalmann Healthcare Conference
Read more →ZYMEZymeworks to Present at Jefferies Virtual Healthcare Conference
Zymeworks to Present at Jefferies Virtual Healthcare Conference
Read more →ZYMEAnnual General Meeting of Shareholders
Annual General Meeting of Shareholders
Read more →ZYMEDocument Zymeworks Reports 2021 First Quarter Financial Results
q1_2021xpressxre.htm EX-99.1 Document Zymeworks Reports 2021 First Quarter Financial Results
Read more →ZYMEZymeworks Announces Succession Plan for Chief Medical Officer
Zymeworks Announces Succession Plan for Chief Medical Officer
Read more →ZYMEZymeworks to Present at Bloom Burton Healthcare Conference
Zymeworks to Present at Bloom Burton Healthcare Conference
Read more →ZYMEZymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT ™ , and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT ™ , and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Read more →ZYMEZymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Read more →ZYMEDocument Zymeworks Reports 2020 Year-End Financial Results
Document Zymeworks Reports 2020 Year-End Financial Results
Read more →ZYMEZymeworks Expands Commercial Team and Creates New R&D Role
Zymeworks Expands Commercial Team and Creates New R&D Role
Read more →ZYMEZymeworks to Participate in Upcoming Investor Conferences and Events
Zymeworks to Participate in Upcoming Investor Conferences and Events
Read more →ZYMEZymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
Read more →ZYMEZanidatamab Data Highlight Durable Antitumor Activity in HER2-Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
Zanidatamab Data Highlight Durable Antitumor Activity in HER2-Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
Read more →ZYMEZymeworks Highlights 2020 Achievements and Announces Corporate Priorities
Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities
Read more →ZYMEZymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49
Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49
Read more →ZYMEZanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Read more →ZYMEExelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
Read more →ZYMEZymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration with BeiGene
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration with BeiGene
Read more →ZYMEZymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer
Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer
Read more →ZYMEZymeworks Receives Orphan Drug Designation from the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Gastric Cancer
Zymeworks Receives Orphan Drug Designation from the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Gastric Cancer
Read more →ZYMEZymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2-Expressing Breast Cancer
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2-Expressing Breast Cancer
Read more →ZYMEDocument Zymeworks Reports 2020 Third Quarter Financial Results
Document Zymeworks Reports 2020 Third Quarter Financial Results
Read more →ZYMEDocument Zymeworks Reports 2020 Second Quarter Financial Results
q22020pressr.htm EX-99.1 Document Zymeworks Reports 2020 Second Quarter Financial Results
Read more →ZYMECorporate Update Webcast and Conference Call Summary
Corporate Update Webcast and Conference Call Summary
Read more →ZYMEZymeworks Announces New Multispecific Antibody Collaboration with Merck
Zymeworks Announces New Multispecific Antibody Collaboration with Merck
Read more →ZYMEZymeworks Announces Corporate Update Webcast and Conference Call
Zymeworks Announces Corporate Update Webcast and Conference Call
Read more →ZYMEZymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference
Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference
Read more →ZYMEDocument Zymeworks Reports 2020 First Quarter Financial Results
q12020pressr.htm EX-99.1 Document Zymeworks Reports 2020 First Quarter Financial Results
Read more →ZYMEZymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
Read more →ZYMEZymeworks Appoints Dr. Kelvin Neu to the Board of Directors
Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
Read more →ZYMEZymeworks Reports 2019 Year-End Financial Results
Zymeworks Reports 2019 Year-End Financial Results
Read more →ZYMEZymeworks to Present at Raymond James 41 st Annual Institutional Investors Conference
Zymeworks to Present at Raymond James 41 st Annual Institutional Investors Conference
Read more →ZYMEZymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares
Read more →ZYMEZymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants
Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants
Read more →ZYMEZymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance ® (palbociclib)
Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance ® (palbociclib)
Read more →ZYMEZymeworks to Present at the J.P. Morgan Healthcare Conference 2020
Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020
Read more →ZYMEZymeworks Highlights Advancing Clinical Collaboration with BeiGene and
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and
Read more →ZYMEZymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress
Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress
Read more →ZYMEZymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement
Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement
Read more →ZYMEZymeworks Reports 2019 Third Quarter Financial Results
Zymeworks Reports 2019 Third Quarter Financial Results
Read more →ZYMEZymeworks to Present at Stifel 2019 Healthcare Conference
Zymeworks to Present at Stifel 2019 Healthcare Conference
Read more →ZYMEZymeworks Announces Phase 1 Data for ZW25 in Combination with
Zymeworks Announces Phase 1 Data for ZW25 in Combination with
Read more →ZYMEZymeworks Appoints Chief People Officer
Zymeworks Appoints Chief People Officer
Read more →ZYMEZymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific
Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific
Read more →ZYMEZymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX
Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX
Read more →ZYMEZymeworks to Participate in Upcoming Investor Conferences
Zymeworks to Participate in Upcoming Investor Conferences
Read more →ZYMEZymeworks Reports 2019 Second Quarter Financial Results
Zymeworks Reports 2019 Second Quarter Financial Results
Read more →ZYMECelgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks
Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks
Read more →ZYME5,555,556 Common Shares
5,555,556 Common Shares
Read more →ZYMEZymeworks to Present at Raymond James Life Sciences and MedTech Conference
Zymeworks to Present at Raymond James Life Sciences and MedTech Conference
Read more →ZYMEZymeworks Adds Accomplished Biopharmaceutical Executives to its Board of Directors
Zymeworks Adds Accomplished Biopharmaceutical Executives to its Board of Directors
Read more →ZYMEZymeworks’ Lead Asset, ZW25, Granted Fast Track Designation from the FDA
Zymeworks’ Lead Asset, ZW25, Granted Fast Track Designation from the FDA
Read more →ZYMEZymeworks Earns Milestone Payment in Merck Collaboration
Zymeworks Earns Milestone Payment in Merck Collaboration
Read more →ZYMEZymeworks to Present at Jefferies 2019 Global Healthcare Conference
Zymeworks to Present at Jefferies 2019 Global Healthcare Conference
Read more →ZYMEZymeworks Announces Corporate Update Conference Call
Zymeworks Announces Corporate Update Conference Call
Read more →ZYMEZymeworks and GSK Expand 2016 Azymetric TM Bispecific Agreement
Zymeworks and GSK Expand 2016 Azymetric TM Bispecific Agreement
Read more →ZYMEZymeworks Enters its First ZymeLink TM Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
Zymeworks Enters its First ZymeLink TM Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics
Read more →ZYMEZymeworks Reports 2019 First Quarter Financial Results
Zymeworks Reports 2019 First Quarter Financial Results
Read more →ZYMEZymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development
Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development
Read more →ZYMEDaiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
Read more →ZYMEZymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019
Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019
Read more →ZYMEZymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers
Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers
Read more →ZYMEZymeworks Reports 2018 Year-End Financial Results
Zymeworks Reports 2018 Year-End Financial Results
Read more →ZYMEZymeworks to Present at Barclays 2019 Global Healthcare Conference
Zymeworks to Present at Barclays 2019 Global Healthcare Conference
Read more →ZYMEZymeworks Reports Second Investigational New Drug (IND)-Submission
Zymeworks Reports Second Investigational New Drug (IND)-Submission
Read more →ZYMEZymeworks Highlights 2018 Achievements and Announces 2019 Priorities
Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities
Read more →ZYMEZymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND‑Enabling Studies at the San Antonio Breast Cancer Symposium
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND‑Enabling Studies at the San Antonio Breast Cancer Symposium
Read more →ZYMEZymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ platforms globally
Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ platforms globally
Read more →ZYMEZymeworks Announces Updated Clinical Data for Novel Bispecific Antibody,
Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody,
Read more →ZYMEZymeworks Reports Financial Results for the Third Quarter of 2018
Zymeworks Reports Financial Results for the Third Quarter of 2018
Read more →ZYMEZymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30 th EORTC-NCI-AACR Symposium
Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30 th EORTC-NCI-AACR Symposium
Read more →ZYMEZymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration
Read more →ZYMEZymeworks to Webcast R&D Briefing
Zymeworks to Webcast R&D Briefing
Read more →ZYMEZymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference
Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference
Read more →ZYMEZymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer
Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer
Read more →ZYMEZymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration
Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration
Read more →ZYMEZymeworks to Present at Wells Fargo Healthcare Conference
Zymeworks to Present at Wells Fargo Healthcare Conference
Read more →ZYMEZymeworks to Present at Canaccord Genuity 38th Annual Growth Conference
Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference
Read more →ZYMEZymeworks Reports Financial Results for the Second Quarter of 2018
Zymeworks Reports Financial Results for the Second Quarter of 2018
Read more →ZYMEZymeworks Closes Previously Announced Public Offering
Zymeworks Closes Previously Announced Public Offering
Read more →ZYME5,400,000 Common Shares
5,400,000 Common Shares
Read more →ZYMEAnnual General and Special Meeting of Shareholders
Annual General and Special Meeting of Shareholders
Read more →ZYMEMATERIAL CHANGE REPORT
MATERIAL CHANGE REPORT
Read more →ZYMEClinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Read more →ZYMEZymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies Two Additional Licenses Granted; Upfront Payment of US$18 Million; Total Potential Transaction Value of up to US$484.7 Million
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies Two Additional Licenses Granted; Upfront Payment of US$18 Million; Total Potential Transaction Value of up to US$484.7 Million
Read more →ZYMEZymeworks to Present at the UBS Global Healthcare Conference 2018
Zymeworks to Present at the UBS Global Healthcare Conference 2018
Read more →ZYMEZymeworks Reports 2018 First Quarter Financial Results
Zymeworks Reports 2018 First Quarter Financial Results
Read more →ZYMEZymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
Read more →ZYMEZymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Data will Highlight the Single Agent Activity of ZW25, a HER2-Targeted Bispecific Antibody
Read more →ZYMEZymeworks and Celgene Expand Bispecific Antibody Collaboration
Zymeworks and Celgene Expand Bispecific Antibody Collaboration
Read more →ZYMEZymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research
Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research
Read more →ZYMEZymeworks Reports 2017 Year-End Financial Results
Zymeworks Reports 2017 Year-End Financial Results
Read more →ZYMEZymeworks to Present at Barclays 2018 Global Healthcare Conference
Zymeworks to Present at Barclays 2018 Global Healthcare Conference
Read more →ZYMEZymeworks Opening Clinical Sites in Canada
Zymeworks Opening Clinical Sites in Canada
Read more →ZYMEZymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Lead Asset (ZW25) Demonstrating Promising Clinical Activity; Growing Number of Pharmaceutical Partners Validate Bispecific Antibody Technology
Read more →ZYMEZymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients
Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients
Read more →ZYMEZymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
Read more →ZYMEZymeworks to Present at Upcoming 2017 Stifel Healthcare Conference
Zymeworks to Present at Upcoming 2017 Stifel Healthcare Conference
Read more →ZYMEMANAGEMENT’S DISCUSSION AND ANALYSIS OF
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
Read more →ZYMEZymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update
Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update
Read more →ZYMEMerck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development
Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development
Read more →ZYMEZymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”)
Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”)
Read more →ZYMEZymeworks to Present at the European Society for Medical Oncology 2017 Congress and Hold Webcast to Review Clinical Results
Zymeworks to Present at the European Society for Medical Oncology 2017 Congress and Hold Webcast to Review Clinical Results
Read more →ZYMEZymeworks Reports Second Quarter 2017 Financial Results
Zymeworks Reports Second Quarter 2017 Financial Results
Read more →ZYMEZymeworks to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017
Zymeworks to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017
Read more →ZYMEZymeworks to Present at 37 th Annual Canaccord Genuity Growth Conference
Zymeworks to Present at 37 th Annual Canaccord Genuity Growth Conference
Read more →ZYMEZymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
Read more →ZYMEDrug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly June 12, 2017
Drug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly June 12, 2017
Read more →ZYMEZymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017)
Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017)
Read more →ZYMEZymeworks Announces Closing of Partial Exercise of Over-Allotment Option for its Initial Public Offering
Zymeworks Announces Closing of Partial Exercise of Over-Allotment Option for its Initial Public Offering
Read more →ZYMEZymeworks Announces Partial Exercise of Over-Allotment Option for its Initial Public Offering
Zymeworks Announces Partial Exercise of Over-Allotment Option for its Initial Public Offering
Read more →ZYMEZymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting
Zymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting
Read more →ZYMEZymeworks Reports First Quarter 2017 Financial Results
Zymeworks Reports First Quarter 2017 Financial Results
Read more →ZYMEZymeworks Thanks Resigning Directors For Their Service
Zymeworks Thanks Resigning Directors For Their Service
Read more →ZYMEZymeworks Announces Closing of Initial Public Offering
Zymeworks Announces Closing of Initial Public Offering
Read more →ZYMEZymeworks Announces Pricing of Initial Public Offering
Zymeworks Announces Pricing of Initial Public Offering
Read more →Competitive Position
How ZYME ranks across every disease it competes inCompetitive Position is a premium feature
See how ZYME ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial